A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

NCT01177163 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Placebo
DRUG: JNJ 28431754 300 mg/placebo
DRUG: JNJ 28431754 100 mg/placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.